Get the Stockscreener App
144.57
3.27%
-4.88
After Hours:
145.11
0.54
+0.37%
Davita Inc stock is traded at $144.57, with a volume of 844.21K.
It is down -3.27% in the last 24 hours and down -4.08% over the past month.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
See More
Previous Close:
$149.45
Open:
$148.61
24h Volume:
844.21K
Relative Volume:
0.80
Market Cap:
$9.66B
Revenue:
$13.64B
Net Income/Loss:
$1.05B
P/E Ratio:
15.13
EPS:
9.555
Net Cash Flow:
$1.31B
1W Performance:
-2.61%
1M Performance:
-4.08%
6M Performance:
+14.74%
1Y Performance:
-1.17%
1-Day Range:
$143.07
$149.32
1-Week Range:
$143.07
$151.96
52-Week Range:
$101.00
$159.42
Davita Inc Stock (DVA) Company Profile
Name
Davita Inc
Sector
Industry
Phone
310-536-2668
Address
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, FMS, ENSG, UHS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
144.57 | 9.99B | 13.64B | 1.05B | 1.31B | 9.555 |
HCA
Hca Healthcare Inc
|
488.58 | 111.48B | 75.60B | 7.78B | 7.69B | 28.38 |
THC
Tenet Healthcare Corp
|
193.56 | 17.10B | 21.31B | 2.37B | 2.53B | 15.49 |
FMS
Fresenius Medical Care Ag Adr
|
22.84 | 12.68B | 22.18B | 1.36B | 2.00B | 1.9216 |
ENSG
Ensign Group Inc
|
197.92 | 11.59B | 5.06B | 344.26M | 370.71M | 5.8446 |
UHS
Universal Health Services Inc
|
180.15 | 11.10B | 17.36B | 1.51B | 849.25M | 23.15 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Aug-07-23 | Upgrade | UBS | Neutral → Buy |
| Nov-01-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-31-22 | Downgrade | UBS | Buy → Neutral |
| Aug-19-22 | Resumed | UBS | Buy |
| Jun-21-22 | Reiterated | BofA Securities | Underperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-12-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-26-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-24-20 | Upgrade | Goldman | Neutral → Buy |
| Nov-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-25-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-11-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-26-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-19 | Upgrade | UBS | Sell → Neutral |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Dec-14-18 | Initiated | Barclays | Overweight |
| Nov-28-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-16-18 | Initiated | UBS | Sell |
| Nov-08-18 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Sep-13-18 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-04-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-12-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-11-17 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-17 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-17 | Downgrade | Jefferies | Buy → Hold |
| Dec-13-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Davita Inc Stock (DVA) Latest News
DaVita Inc. stock (US23918K1088): Is kidney care demand strong enough to drive steady investor retur - AD HOC NEWS
DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
DaVita Inc. stock rises Monday, still underperforms market - MarketWatch
DaVita Inc stock (US23804L1035): Why its kidney care dominance matters more now for investors - AD HOC NEWS
DaVita Inc. (DVA) Is Down 9% This Year. Here Is Why - MSN
Will DaVita’s (DVA) Push Into Patient-Centric Data Access Reshape Its Digital Health Narrative? - Sahm
Assessing DaVita (DVA) Valuation After Earnings Beat Buyback Debate And EPS Guidance Questions - Yahoo Finance
Here's why you should retain DaVita stock in your portfolio for now - MSN
DaVitaFurther Upside Is Trickier (Rating Downgrade) (NYSE:DVA) - Seeking Alpha
DaVita Inc. stock (US23918K1088): Is its dialysis dominance strong enough to unlock new upside? - AD HOC NEWS
DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
Reasons to Keep DaVita Stock in Your Investment Portfolio at This Time - Bitget
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - TradingView — Track All Markets
Zacks Downgrades DaVita Stock Rating - National Today
DaVita Inc stock: What investors need to know about its dialysis dominance now - AD HOC NEWS
California law limiting dialysis providers' profits voided by US appeals court - Reuters
DaVita Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
DaVita, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Day in the Life: Ansel, DaVita Home Hemodialysis Registered Nurse - CSRwire
DaVita's "Move It With Purpose" Sets Record Participation in Support of Global Health - csrwire.com
Day in the Life: Jena, DaVita Social Worker - CSRwire
Day in the Life: Cristina, DaVita PD Registered Nurse - CSRwire
DVA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
DaVita Inc. stock underperforms Thursday when compared to competitors - MSN
DaVita Inc. (DVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
DaVita Inc. (DVA.MX) Stock Price, News, Quote & History - Yahoo! Finance Canada
DaVita Entities’ Drug Purchases Exempt From Louisiana Sales Tax - news.bloombergtax.com
DaVita Inc. stock: Steady earnings beat amid market dips—what's next? - AD HOC NEWS
DaVita Arms Freed From Local La. Tax On Medicare Drugs - Law360
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know - Yahoo Finance
DaVita HealthCare (DVA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
DaVita Inc Stock: Leading Dialysis Provider Faces Evolving Healthcare Landscape in 2026 - AD HOC NEWS
DaVita: A Digital Guardian: AI-Powered Insights Bring Patients and Clinicians Closer - FinanzNachrichten.de
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock - Yahoo Finance
Here's Why DaVita HealthCare (DVA) Fell More Than Broader Market - Yahoo Finance
DaVita Inc. stock underperforms Monday when compared to competitors - MarketWatch
Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health - GlobeNewswire Inc.
Assenagon Asset Management Trims DaVita Stake - National Today
Assenagon Asset Management S.A. Trims Holdings in DaVita Inc. $DVA - MarketBeat
DaVita stock dips 1.49% as company promotes home dialysis benefits - Traders Union
Wedge Capital Management L L P NC Purchases 45,998 Shares of DaVita Inc. $DVA - MarketBeat
SG Americas Securities LLC Increases Stake in DaVita Inc. $DVA - MarketBeat
DaVita (FRA:TRL) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
DaVita Inc. stock outperforms competitors despite losses on the day - MarketWatch
Why DaVita Inc (DVA) Is Set to Outperform the Market: Insights i - GuruFocus
DaVita Inc. (NYSE:DVA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Should Value Investors Buy DaVita (DVA) Stock? - Yahoo Finance
Vanguard disaggregates holdings; DVA shows 0 shares (DVA) - Stock Titan
Davita Inc Stock (DVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.37%
5.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):